Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Pieris Pharmaceuticals In...

    NASDAQ: PIRS · Real-Time Price · USD
    13.60
    -2.51 (-15.58%)
    At close: Dec 13, 2024, 10:00 PM

    Pieris Pharmaceuticals Statistics

    Share Statistics

    Pieris Pharmaceuticals has 1.32M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 1.32M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 1.08%

    Shares Floating

    n/a
    		 808.12K

    Failed to Deliver (FTD) Shares

    n/a
    		 932

    FTD / Avg. Volume

    n/a
    		 4.21%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -0.67 and the forward PE ratio is null. Pieris Pharmaceuticals's PEG ratio is 0.02.

    PE Ratio

    n/a
    		 -0.67

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0.38

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.61

    P/FCF Ratio

    n/a
    		 -0.3

    PEG Ratio

    n/a
    		 0.02
    Financial Ratio History

    Enterprise Valuation

    Pieris Pharmaceuticals has an Enterprise Value (EV) of -1M.

    EV / Sales

    n/a
    		 -0.02

    EV / EBITDA

    n/a
    		 0.04

    EV / EBIT

    n/a
    		 0.02

    EV / FCF

    n/a
    		 0.02

    Financial Position

    The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 3.24

    Quick Ratio

    n/a
    		 3.24

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is -91.72% and Return on Invested Capital is -111.2%.

    Return on Equity

    n/a
    		 -91.72%

    Return on Assets

    n/a
    		 -63.45%

    Return on Invested Capital

    n/a
    		 -111.2%

    Revenue Per Employee

    n/a
    		 $930,652.17

    Profits Per Employee

    n/a
    		 $-533,543.48

    Employee Count

    n/a
    		 46

    Asset Turnover

    n/a
    		 1.11

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 14% in the last 52 weeks. The beta is 0.66, so Pieris Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.66

    52-Week Price Change

    n/a
    		 14%

    50-Day Moving Average

    n/a
    		 16.45

    200-Day Moving Average

    n/a
    		 14.06

    Relative Strength Index (RSI)

    n/a
    		 28.17

    Average Volume (20 Days)

    n/a
    		 22,126

    Income Statement

    In the last 12 months, Pieris Pharmaceuticals had revenue of 42.81M and earned -24.54M in profits. Earnings per share was -21.8.

    Revenue

    n/a
    		 42.81M

    Gross Profit

    n/a
    		 1.01M

    Operating Income

    n/a
    		 -29.76M

    Net Income

    n/a
    		 -24.54M

    EBITDA

    n/a
    		 -22.76M

    EBIT

    n/a
    		 -24.54M

    Earnings Per Share (EPS)

    n/a
    		 -21.8
    Full Income Statement

    Balance Sheet

    The company has 17.4M in cash and 0 in debt, giving a net cash position of 17.4M.

    Cash & Cash Equivalents

    n/a
    		 17.4M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -314.96M

    Total Assets

    n/a
    		 20.52M

    Working Capital

    n/a
    		 16.27M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -53.82M and capital expenditures -171K, giving a free cash flow of -53.99M.

    Operating Cash Flow

    n/a
    		 -53.82M

    Capital Expenditures

    n/a
    		 -171K

    Free Cash Flow

    n/a
    		 -53.99M

    FCF Per Share

    n/a
    		 -47.96
    Full Cash Flow Statement

    Margins

    Gross margin is 2.36%, with operating and profit margins of -69.51% and -57.33%.

    Gross Margin

    n/a
    		 2.36%

    Operating Margin

    n/a
    		 -69.51%

    Pretax Margin

    n/a
    		 -57.33%

    Profit Margin

    n/a
    		 -57.33%

    EBITDA Margin

    n/a
    		 -53.17%

    EBIT Margin

    n/a
    		 -69.51%

    FCF Margin

    n/a
    		 -126.12%

    Dividends & Yields

    PIRS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -149.73%

    FCF Yield

    n/a
    		 -329.38%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for PIRS.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Apr 23, 2024. It was a backward split with a ratio of 1:80.

    Last Split Date

    n/a
    		 Apr 23, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:80

    Scores

    Altman Z-Score

    n/a
    		 -21.55

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist